AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Ja weil die auch von 80 $ auf 2 $ herunter gegangen sind wie fast alle Biotech.

Abcellera ist Müll ich gebe es auf bald nur minus in dem Müll Laden

Nächten Wochen? Direkt um 22:00 Uhr. Und Morgen 17:00 SITC.

Prelude ist unbedeutende Pommes Bude mit 100 mio marcet cap.

Prelude war + 18 % heute. Es sind sicher Analysen erschienen.

Ich hoffe das Management kommt mit guten News die nächsten Wochen. Was ein abverkauf.

'WILMINGTON, Del. & VANCOUVER, British Columbia--(BUSINESS WIRE)-- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer. The collaboration combines Prelude’s expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera’s antibody discovery and development engine to generate novel precision antibody drug conjugates (ADCs). The first program, which benefits from a lead panel of antibodies previously discovered by AbCellera, is focused on ADCs to broaden the reach of Prelude’s small molecule SMARCA2 selective degraders to address a larger patient population.' https://mail.google.com/mail/u/0/#inbox/WhctKKZPBNcjGtMRFMcnRlzFDpHMDhwzTkZVDjlMdkctdxgCgRpNrJQQCJGVwnHjzZkJmdv

Die Zahlen sind nicht wichtig. Wichtig ist den wissenschaftlichen Fortschritt.

Katastrophe

https://investors.abcellera.com/news/news-releases/2023/AbCellera-Reports-Q3-2023-Business-Results/default.aspx

https://www.stocktitan.net/news/ABCL/ab-cellera-reports-q3-2023-business-ih8mwiohn3c3.html

2-3 $ worst case Szenario.

Würde mich nicht wündern das wir unter einen Euro kommen

Geldvernichtungsanlage😵

Wenn man denkt es kann nicht weiter fallen muss man sich nur abcellera ansehen

Contrasting Price Targets and Analyst Ratings for AbCellera Biologics Yasmim Mendonça by Yasmim Mendonça October 13, 2023 in News Reading Time: 2 mins read On October 13, 2023, Piper Sandler analyst Allison Bratzel initiated coverage of AbCellera Biologics, expressing optimism with an Overweight rating and setting a price target of $20. It is worth noting, however, that there are contrasting price targets for AbCellera Biologics from different sources. For instance, MarketBeat currently suggests a price target of $23.13, while TipRanks indicates an average price target of $23.33, with a high forecast of $34.00 and a low forecast of $12.00. It is crucial to understand that analyst ratings and price targets are subjective and can evolve over time due to various factors. https://beststocks.com/contrasting-price-targets-and-analyst-ratings/